A detailed history of Legal & General Group PLC transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 32,477 shares of OLMA stock, worth $297,814. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,477
Previous 32,477 -0.0%
Holding current value
$297,814
Previous $387,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.41 - $16.46 $3,195 - $5,053
307 Added 0.95%
32,477 $387,000
Q2 2024

Aug 14, 2024

BUY
$8.73 - $13.99 $42,567 - $68,215
4,876 Added 17.86%
32,170 $348,000
Q1 2024

May 14, 2024

BUY
$10.95 - $16.62 $30,232 - $45,887
2,761 Added 11.25%
27,294 $308,000
Q4 2023

Feb 15, 2024

BUY
$10.53 - $17.14 $232,776 - $378,896
22,106 Added 910.84%
24,533 $344,000
Q3 2023

Nov 14, 2023

SELL
$8.19 - $12.98 $1,253 - $1,985
-153 Reduced 5.93%
2,427 $29,000
Q2 2023

Aug 14, 2023

BUY
$3.22 - $9.65 $8,307 - $24,897
2,580 New
2,580 $23,000
Q2 2022

Aug 22, 2022

SELL
$2.04 - $4.61 $9,687 - $21,892
-4,749 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$3.89 - $9.43 $2,139 - $5,186
-550 Reduced 10.38%
4,749 $20,000
Q4 2021

Feb 14, 2022

BUY
$8.75 - $30.71 $26,311 - $92,344
3,007 Added 131.2%
5,299 $49,000
Q3 2021

Nov 15, 2021

BUY
$22.96 - $30.13 $26,404 - $34,649
1,150 Added 100.7%
2,292 $63,000
Q2 2021

Aug 12, 2021

SELL
$21.15 - $36.14 $2,178 - $3,722
-103 Reduced 8.27%
1,142 $32,000
Q1 2021

May 17, 2021

BUY
$27.81 - $53.64 $34,623 - $66,781
1,245 New
1,245 $41,000

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $371M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.